Loading the session
Loading the session
Loading instrument
$287.34
+0.47%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:21 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Trailing P/E of 81.2 against a median of 40.0 across 6 peers named in its company record (range 13.7 to 115.7).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026
1 month: +7.6% (SPY −2.6%, XLV +9.9%). 3 months: +17.3% (SPY −2.2%, XLV +13.5%). 1 year: +34.9% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ABBV, SPY and XLV · as of 3 Nov 2026
Closed at $286.00 on 3 Nov 2026: 4.3% below the 52-week high of $298.74 (30 Oct 2026) and 49.9% above the low of $190.75 (29 Apr 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
The 3 Nov 2026 close of $286.00 was 5.8% above its 50-day average ($270.20) and 20.3% above its 200-day average ($237.81). It has closed above the 200-day for 95 sessions, since 22 Jun 2026. The 50-day average crossed above the 200-day on 9 Jul 2026, 82 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
15.6M shares were sold short at the 15 Oct 2026 settlement, 0.9% of the 1.77B shares outstanding; covering them would take 2.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 3 Nov 2026 close
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
April 4, 2025
−7.28%November 11, 2024
−12.57%April 27, 2023
−7.99%